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1. Introduction
Identifying biomarkers that can be used as approximate surrogates for clinical end-
points in randomized trials is useful for many reasons including shortening studies,
reducing costs, sparing study participants discomfort, and elucidating treatment eﬀect
mechanisms. As a speciﬁc example motivating this work, an objective of placebo-
controlled preventive HIV vaccine eﬃcacy trials is the evaluation of various vaccine-
induced immune responses as surrogate endpoints for HIV infection. Development of
such a surrogate is a central goal of vaccine research; for example the Foundation of
the NIH and the Gates Foundation list it as one of the 14 “Grand Challenges in Global
Health.” An immunological surrogate would be useful for several purposes including
guiding iterative development of immunogens between basic and clinical research, guid-
ing regulatory decisions and public immunization policy, and bridging eﬃcacy of a
vaccine observed in a trial to a new setting.
Statistical methods for evaluating surrogate endpoints has emerged as an important
research area (Weir and Walley, 2006). This ﬁeld was catalyzed by Prentice’s (1989)
deﬁnition of a surrogate endpoint as a replacement endpoint that provides a valid test
of the null hypothesis of no treatment eﬀect on the clinical endpoint. The two main
criteria for checking this deﬁnition are: (i) the distribution of the clinical endpoint
conditional on the surrogate is the same as the distribution of the clinical endpoint
conditional on the surrogate and treatment (i.e., all of the clinical treatment eﬀect is
“mediated” through the surrogate); and (ii) the surrogate and clinical endpoints are
correlated. Frangakis and Rubin (2002) (henceforth FR) observed that this deﬁnition
is based on observable random variables, and named a biomarker satisfying criterion
(i) a “statistical surrogate.” Since 1989, most of the surrogate-evaluation methods have
been designed to check if a biomarker is a statistical surrogate. These methods include
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estimation of the proportion of the treatment eﬀect explained (Freedman et al., 1992;
Lin, Fleming, and DeGruttola, 1997; Wang and Taylor, 2002) and of the relative eﬀect
and adjusted association (Buyse and Molenberghs, 1998), as well as meta-analysis
(Daniels and Hughes, 1997; Buyse et al., 2000; Gail, 2000).
Treatment eﬀects adjusted for a variable measured after randomization (called net
eﬀects) are susceptible to post-randomization selection bias (e.g., Rosenbaum, 1984;
Robins and Greenland, 1992; Hudgens, Hoering, and Self, 2003). Since potential sur-
rogates are measured after randomization, criterion (i) deﬁning a statistical surrogate
is based on net eﬀects. FR pointed out that this deﬁnition does not have a causal in-
terpretation, and proposed a new surrogate deﬁnition based on principal causal eﬀects.
FR introduced a potential outcomes framework for evaluating “principal surrogates,”
but statistical methods for doing so have not been elaborated. A recent review paper
noted that FR “present a convincing case for the principal surrogate deﬁnition” and
called for such elaborations (Weir and Walley, 2006). The only work in this area of
which we are aware is Taylor et al.’s (2005) summary measure of surrogate quality.
Here we develop an approach for evaluating a principal surrogate from a single
large clinical trial, which to our knowledge constitutes the ﬁrst such method. Follow-
ing Follmann (2006), our approach uses baseline covariates to predict missing potential
biomarker outcomes. After deﬁning and comparing statistical and principal surrogates
in Section 2, in Section 3 we introduce a causal eﬀect predictiveness surface, plus asso-
ciated summary parameters, which serve as appropriate estimands for quantifying how
well a biomarker predicts population level causal clinical treatment eﬀects. Motivated
by the problem of assessing an immune response to an HIV vaccine as a surrogate
endpoint for HIV infection, in Section 4 we consider the important special case where
the biomarker has no variability in one of the treatment arms. For this setting we de-
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velop an estimated likelihood-based method for estimating the causal estimands based
on case-cohort sampling of the biomarkers. In Section 5 we evaluate the method in
simulations based on a vaccine trial, and in Section 6 we conclude with discussion.
2. Comparison of Statistical and Principal Surrogates
2.1 Statistical Surrogates are Based on Net Eﬀects, not Causal Eﬀects
Throughout we consider a randomized trial with treatment assignment Z (Z = 1
or 0), a biomarker endpoint S measured at ﬁxed time t0 after treatment assignment,
and a binary clinical endpoint Y (Y = 1 for disease, 0 otherwise) measured after t0.
Because S must be measured prior to disease to evaluate it as a potential surrogate,
the analysis is restricted to subjects disease free at t0; denote this evaluability criterion
by the indicator V = 1. The biomarker S is only measured in those with V = 1,
and otherwise is undeﬁned (denoted by S = ∗). Following FR, methods for evaluating
statistical surrogates are based on comparing the risk distributions
risk(s|Z = 1) ≡ Pr(Y obs = 1|Z = 1, V obs = 1, Sobs = s) and
risk(s|Z = 0) ≡ Pr(Y obs = 1|Z = 0, V obs = 1, Sobs = s),
where obs indicates the variable is observed. FR deﬁned S to be a statistical surrogate
if, for all ﬁxed values s of S, risk(s|Z = 1) = risk(s|Z = 0). The full mediation
criterion (i) requires that a treatment eﬀect on Sobs is necessary and suﬃcient for a
treatment eﬀect on Y obs; statistical surrogacy is the necessity part of (i).
Because S and V are measured after randomization, a comparison of risk(s|Z = 1)
and risk(s|Z = 0) measures treatment diﬀerences due to a mixture of the causal
treatment eﬀect and any diﬀerences in characteristics between treatment 1 subjects
who have response level s, {Z = 1, V obs = 1, Sobs = s}, and treatment 0 subjects
who have response level s, {Z = 0, V obs = 1, Sobs = s} (i.e., the net eﬀect). If there
is no treatment eﬀect on S, then the net eﬀect may approximate the causal eﬀect.
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Biomarkers of interest are usually aﬀected by treatment, however, and the greater the
treatment eﬀect on S, the greater the anticipated discrepancy between the net eﬀect
and the causal eﬀect of interest. FR concluded that because the statistical surrogate
deﬁnition is based on net eﬀects, employing it for evaluating a surrogate may mislead
about the biomarker’s capacity for reliably predicting clinical treatment eﬀects.
2.2 Evaluating Statistical Surrogates Based on the PTE
Freedman et al. (1992) introduced the proportion of treatment eﬀect explained
(PTE) as a quantitative measure of the quality of a biomarker as a statistical surrogate,
and several methods for evaluating surrogates have been developed based on the PTE
(Lin, Fleming, and DeGruttola, 1997; Wang and Taylor, 2002). To deﬁne the PTE,
consider two generalized linear models:
gY {E(Y
obs
i |Zi, V
obs
i = 1)} = β0 + β1Zi,
gY {E(Y
obs
i |Zi, V
obs
i = 1, S
obs
i )} = θ0 + θ1Zi + θ2S
obs
i ,
where gY {·} is a known link function. For a binary clinical endpoint Y , Freedman et
al. (1992) deﬁned the PTE as PTE ≡ 1− θ1/β1, which equals
1−
gY {E(Y
obs
i |Zi = 1, V
obs
i = 1, S
obs
i )} − gY {E(Y
obs
i |Zi = 0, V
obs
i = 1, S
obs
i )}
gY {E(Y obsi |Zi = 1, V
obs
i = 1)} − gY {E(Y
obs
i |Zi = 0, V
obs
i = 1)}
.
A perfect statistical surrogate has PTE = 1, which means there is a treatment eﬀect
on the clinical endpoint (β1 = 0) and no net treatment eﬀect after adjusting for the
observed surrogate (θ1 = 0). The latter condition is implied by risk(s|Z = 1) =
risk(s|Z = 0) for all ﬁxed values s of S, showing that FR’s deﬁnition of a statistical
surrogate implies PTE = 1. The numerator θ1 of the PTE is a net eﬀect, whereas
under standard assumptions A1 and A2 made for a randomized trial given below,
the denominator β1 is a causal eﬀect. Consequently, the common description of the
PTE as a measure of the amount of the clinical treatment eﬀect mediated through the
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surrogate seems misleading, because “mediation” should only reﬂect a causal eﬀect.
The post-randomization bias inherent in the PTE suggests that alternative summary
measures, based solely on causal eﬀects, should be considered.
2.3 Deﬁnition of a Principal Surrogate Endpoint
We introduce the potential outcomes notation (Rubin, 1986) and assumptions that
will be used for deﬁning and identifying the causal estimands of interest. For sub-
ject i, let Yi(Z) be the potential clinical endpoint (i.e., disease) under assignment to
treatment Z, Z = 0, 1. Similarly deﬁne potential outcomes Si(Z) for the biomarker
endpoint, which is measured at time t0 after treatment assignment, and let Vi(Z)
be the potential indicators of whether the ith subject is disease free at t0. Note
that Si(Z) is undeﬁned if Vi(Z) = 0; in this case Si(Z) = ∗. We suppose that
(Vi(1), Vi(0), Si(1), Si(0), Yi(1), Yi(0)), i = 1, . . . , n, are iid, and for simplicity assume
no drop-out. We also make the following assumptions A1, A2 (Rubin 1986), and A3.
A1 Stable Unit Treatment Value Assumption (SUTVA)
A2 Ignorable Treatment Assignments: Zi is independent of (Vi(1), Vi(0), Si(1), Si(0),
Yi(1), Yi(0)) for all i
A3 Equal Individual Clinical Risk Up to Time t0: Vi(1) = 1 if and only if Vi(0) = 1.
A1 states that the potential outcomes (Vi(1), Vi(0), Si(1), Si(0), Yi(1), Yi(0)) for each
subject are independent of the treatment assignments of other subjects, which implies
so-called “consistency”, (Vi(Zi), Si(Zi), Yi(Zi)) = (V
obs
i , S
obs
i , Y
obs
i ). A2 holds for ran-
domized and blinded trials. A3 will be needed for identifying the causal estimand based
on data from subjects observed to be at risk at t0. This assumption will approximately
hold if the risk of disease is the same in the two arms up to t0, or if most subjects
are at risk for disease at t0, e.g., if t0 is near baseline. A1-A3 often hold in our moti-
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vating application. In particular, A3 should approximately attain in the two ongoing
HIV vaccine eﬃcacy trials, since the candidate immunological surrogate endpoints are
measured near baseline (at t0 = 8 weeks) (Mehrotra, Li, and Gilbert, 2006).
With these preliminaries, we now deﬁne a principal surrogate endpoint. FR sug-
gested that a surrogate S should satisfy the following property:
Causal Necessity: S is necessary for the eﬀect of treatment on the outcome Y in the
sense that an eﬀect of treatment on Y can occur only if an eﬀect of treatment on S has
occurred. At the individual level, this means that Si(1) = Si(0) implies Yi(1) = Yi(0).
A population level deﬁnition of Causal Necessity, which is used in our approach to
surrogate evaluation, is given below.
FR deﬁned the basic principal stratiﬁcation P0 with respect to the post-randomization
variable S as the partition of units i = 1, . . . , n such that within any set of P0, all units
have the same vector (Si(1), Si(0)). A principal stratiﬁcation is a partition of units
whose sets are unions of sets in P0. Estimands that condition on a principal stratiﬁca-
tion are causal because, by construction, the stratiﬁcation is unaﬀected by treatment.
FR deﬁned a biomarker S to be a principal surrogate endpoint if, for all ﬁxed s1 = s0,
the comparison between
risk(1)(s1, s0) ≡ Pr(Yi(1) = 1|Vi(1) = 1, Vi(0) = 1, Si(1) = s1, Si(0) = s0) and
risk(0)(s1, s0) ≡ Pr(Yi(0) = 1|Vi(1) = 1, Vi(0) = 1, Si(1) = s1, Si(0) = s0)
results in equality. FR did not explicitly condition on Vi(1) = Vi(0) = 1 in their
deﬁnition; however implicitly they must have, since (Si(1), Si(0)) is only deﬁned if
Vi(1) = Vi(0) = 1. Henceforth, for brevity all probability statements that involve
Si(1) and Si(0) are implicitly intersected with {Vi(1) = Vi(0) = 1}. A contrast in
risk(1)(s1, s0) and risk(0)(s1, s0) measures a population level or average causal eﬀect on
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Y for subjects with {Si(1) = s1, Si(0) = s0}. Thus with FR’s deﬁnition S is a principal
surrogate if subjects with no causal eﬀect on the biomarker have no average causal
eﬀect on the clinical endpoint. This is a population version of Causal Necessity, which
we call Average Causal Necessity. For reference, we deﬁne this property as follows.
Average Causal Necessity: risk(1)(s1, s0) = risk(0)(s1, s0) for all ﬁxed s1 = s0.
Biomarkers with the greatest utility for predicting clinical treatment eﬀects will
not only be necessary for a clinical eﬀect, but also suﬃcient. Causal Suﬃciency can be
deﬁned as follows:
Causal Suﬃciency: S is suﬃcient for the eﬀect of treatment on the outcome Y in
the sense that an eﬀect of treatment on S implies an eﬀect of treatment on Y . At the
individual level, this means that Si(1) = Si(0) implies Yi(1) = Yi(0).
Often Causal Suﬃciency is at least as important scientiﬁcally as Causal Necessity.
For example, knowing that an antibody titer > 1000 is suﬃcient for a vaccine to protect
an individual against HIV infection is exactly the information needed to use titer as a
reliable predictor of protection. We deﬁne Average Causal Suﬃciency as
Average Causal Suﬃciency: risk(1)(s1, s0) = risk(0)(s1, s0) for all ﬁxed s1 = s0,
and suggest a reﬁned deﬁnition of a principal surrogate endpoint:
Principal Surrogate Endpoint: A biomarker S that satisﬁes both Average Causal
Necessity and Average Causal Suﬃciency as deﬁned above.
Heretofore we use this deﬁnition of a principal surrogate endpoint.
Evaluating a principal surrogate is challenging due to the missing data, which re-
sults from observing only one of (Vi(1), Si(1), Yi(1)) or (Vi(0), Si(0), Yi(0)) from each
subject (Holland, 1986). At present, it is not clear when this missing data problem can
be satisfactorily overcome to provide practically useful inferential tools for evaluating
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principal surrogates. Inaccurate modeling of the missing data could lead to bias in
assessing whether a biomarker is a principal surrogate, and it is unclear when this bias
will exceed that inherent in the deﬁnition of a statistical surrogate. However, there
are particular settings where it is auspicious to solve the missing data problem under
assumptions that are all plausible or testable, in which case it is relatively easy to
evaluate a principal surrogate. In Sections 3 and 4, we develop an evaluation method
for one such setting: where the biomarker has no variation for one treatment arm.
2.4 Illustration of Statistical versus Principal Surrogates
To illustrate the more useful scientiﬁc interpretation of a principal than statistical
surrogate, we consider a placebo-controlled vaccine trial where Y is infection and S is
a binary, taking values positive or negative immune response (vaccine “take” or not).
We suppose Si(0) = 0 for all i. The top half of Table 1 presents a perfect principal
surrogate, wherein subjects in the “not take” principal stratum have a 30% chance of
becoming infected under either assignment vaccine or placebo (0% protection), and
subjects in the “take” stratum have a 0% chance of becoming infected under vaccine
assignment and a 15% chance under placebo assignment (100% protection). Therefore
the vaccine eﬀect on the immune response predicts perfectly whether a subject is
protected, and S is a perfect principal surrogate. However, S is not a statistical
surrogate, because for subjects with Sobsi = 0, the probabilities of infection Pr(Y
obs
i =
1|Sobsi = 0, Zi = z) for vaccine and placebo recipients are unequal (0.3 for Z = 1 and 0.2
for Z = 0). Thus the deﬁnition of a statistical surrogate misses the predictive capacity
of S (a “false negative”). The bottom half of Table 1 presents an immune response
that does not predict whether a subject is protected at all yet is a statistical surrogate
(a “false positive”). The statistical surrogate deﬁnition fails in these examples because
of the causal vaccine eﬀect on S, with 67% versus 0% responders in the vaccine and
9
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placebo arms, and the large amount of selection bias that is reﬂected in the net eﬀect.
This bias could arise because vaccine recipients who fail to mount an immune response
have relatively weak immune systems, which places them at high risk for infection.
3. Causal Eﬀect Predictiveness Surface
3.1 Quantitation of Associative and Dissociative Eﬀects
FR suggested that the quality of a surrogate be measured by its “associative eﬀects”
relative to its “dissociative eﬀects”, with a ‘good’ surrogate having large associative
eﬀects and small dissociative eﬀects. As deﬁned in equations 5.3 and 5.4 of FR, an
associative eﬀect is a comparison between the ordered sets
{Yi(1) : Si(1) = Si(0)} and {Yi(0) : Si(1) = Si(0)},
and a dissociative eﬀect is a comparison between the ordered sets
{Yi(1) : Si(1) = Si(0)} and {Yi(0) : Si(1) = Si(0)}.
For the purpose of quantifying these eﬀects, we introduce a causal eﬀect predictive-
ness surface (CEP surface). Let CE ≡ h(Pr(Yi(1) = 1), P r(Yi(0) = 1)) be the overall
causal eﬀect of treatment on the clinical endpoint, where h(·, ·) is a known contrast
function satisfying h(x, x) = 0, for example h(x, y) = x− y or log(x/y). Let
CEP risk(s1, s0) ≡ h(risk(1)(s1, s0), risk(0)(s1, s0))
be this contrast conditional on {Si(1) = s1, Si(0) = s0}. Note that CEP
risk(s, s) = 0
for all s is a population version of no dissociative eﬀects, and is equivalent to Average
Causal Necessity, whereas CEP risk(s1, s0) = 0 for all s1 = s0 is a population version
of 100% associative eﬀects, and is equivalent to Average Causal Suﬃciency. Therefore
the criteria for a principal surrogate can be checked by estimating the CEP surface.
Moreover, biomarkers with capacity to predict clinical treatment eﬀects will usually
10
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have |CEP risk(s1, s0)| monotone in |s1 − s0|, reﬂecting the situation that on average
persons with a greater causal eﬀect on the marker have a greater causal eﬀect on
the clinical endpoint. We refer to the capacity of a biomarker to reliably predict the
population level causal eﬀect of treatment on the clinical endpoint as the biomarkers’
surrogate value, which can be quantiﬁed by both the nearness of |CEP risk(s1, s0)| to 0
for s1 near s0, and by the extent to which |CEP
risk(s1, s0)| increases with |s1 − s0|.
The CEP surface can alternatively be deﬁned in terms of percentiles of the marker
S. To formulate this, consider Huang et al.’s (2006) proposal to judge the value of
a marker S for predicting disease Y by the predictiveness curve, R(v) ≡ Pr(Y obs =
1|F (Sobs) = v), v ∈ [0, 1], where F is the cdf of Sobs. If F−1 exists, then
R(v) = Pr(Y obs = 1|Sobs = F−1(v)) = risk(Sobs = F−1(v)),
i.e., R(v) is risk as a function of the quantiles of Sobs, which provides a common scale
for comparing multiple markers. If we assume R(v) is a monotone increasing function
of v, then R(v) = p implies v percent of the population have risk less than or equal to p.
The predictiveness curve R(v) usefully informs about both absolute risks at diﬀerent
marker quantiles and the frequency of these risks in the population. Huang, Pepe,
and Feng (2006) proposed plotting an estimate of R(v) versus v as a graphical tool
for assessing and comparing the predictiveness of markers. A predictive marker is one
with R(v) monotone (or approximately so) in v with large |R(1)− R(0)|.
Applying these ideas, we propose a scale-independent version of the causal eﬀect
predictiveness surface, CEPR(v1, v0) ≡ h(R(1)(v1, v0), R(0)(v1, v0)), where
R(1)(v1, v0) ≡ Pr(Y (1) = 1|S(1) = F
−1
(1) (v1), S(0) = F
−1
(1) (v0)) and
R(0)(v1, v0) ≡ Pr(Y (0) = 1|S(1) = F
−1
(1) (v1), S(0) = F
−1
(1) (v0)).
In this deﬁnition, S(1) and S(0) are standardized relative to the distribution F(1) of
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S(1). Using the same reference distribution for S(1) and S(0) makes the marker values
under assignment to the two arms comparable, ensuring S(1) = S(0) if and only if
v1 = v0. With h(x, y) = x − y, the volume between CEP
R(·, ·) and the zero-plane
equals CE = Pr(Y (1) = 1)− Pr(Y (0) = 1). The nearer |CEP R(v1, v0)| is to zero for
|v1 − v0| near zero and the larger |CEP
R(v1, v0)| is for large |v1 − v0|, the greater the
causal treatment eﬀect on S is predictive of the average causal treatment eﬀect on Y .
To illustrate the interpretation of CEPR(v1, v0), we consider the unidirectional
situation where interest is in assessing if higher responses of S if assigned treatment
1 (Si(1) > Si(0)) predict clinical beneﬁt of treatment 1. For example, this situation
might occur in trials of active treatment 1 versus placebo 0. In Figure 1(i), the fact
that CEPR(v1, v0) = CE for all (v1, v0) indicates the biomarker has no surrogate
value. In contrast, in Figure 1(ii) CEPR(v1, v0) = 0 for all v1 ≤ v0 and |CEP
R(v1, v0)|
is monotone in v1 − v0 with large amount of increase, reﬂecting a biomarker with high
surrogate value.
Next, we consider the interpretation of the CEP surface in the special case where
Si(0) is constant. We refer to this case as A4:
A4 Uniform Biomarkers: Si(0) = c for all i for some constant c
HIV vaccine trials ﬁt case A4, because S is an HIV-speciﬁc immune response, which
will be 0 for all subjects in the placebo arm Z = 0, since vaccine antigens must be
presented to the immune system to induce a response (Gilbert et al., 2005). Under
A4 the CEP risk(s1, c) surface is a curve in s1 and the CEP
R(v1, F(1)(c)) surface is a
curve in v1. The dissociative eﬀect can be measured by CEP
R(F(1)(c), F(1)(c)), and
the associative eﬀects by CEPR(v1, F(1)(c)) for v1 = F(1)(c). For example, with c = L
the lower bound of S (e.g., an assay detection limit), the nearer CEP R(F(1)(c), F(1)(c))
is to zero and the greater the increase of |CEPR(v1, F(1)(c))| with v1 > F(1)(c), the
12
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greater the surrogate value of the biomarker (Figure 2). This kind of plot provides an
interpretable way to compare the surrogate value of multiple biomarkers.
3.2 Summary Measures of Surrogate Value
We suggest parameters that summarize the surrogate value of a biomarker, which
are functionals of the CEP surface. Again we consider the situation where interest is
in assessing whether Si(1) > Si(0) predicts clinical beneﬁt of treatment 1 (Yi(1) = 0
and Yi(0) = 1). To summarize the asociative and dissociative eﬀects, we consider the
expected associative eﬀect (EAE) and the expected dissociative eﬀect (EDE):
EAE(w) ≡ E[w(S(1), S(0))CEP risk(S(1), S(0))|S(1) > S(0)] (1)
EDE ≡ E[CEP risk(S(1), S(0))|S(1) ≤ S(0)], (2)
where w(·, ·) is a known nonnegative weight function. The EAE(w) can equivalently
be written as EAE(w) =
∫
v1>v0
w(v1, v0)CEP
R(v1, v0)dv1dv0/Pr(Si(1) > Si(0)) and
similarly for EDE. Thus EAE(w = 1) is the volume between CEP R(v1, v0) and the
zero-plane in the v1 > v0 quadrant divided by Pr(Si(1) > Si(0)), and EDE is the
volume between CEPR(v1, v0) and the zero-plane in the v1 ≤ v0 quadrant divided by
Pr(Si(1) ≤ Si(0)).
We also deﬁne the proportion associative eﬀect by
PAE(w) ≡
|EAE(w)|
|EDE|+ |EAE(w)|
. (3)
The PAE(w) is the magnitude of the expected associative eﬀect relative to the com-
bined magnitude of the expected associative eﬀect and the expected dissociative eﬀect.
Values PAE(w) ≤ 0.5 suggest the biomarker has no surrogate value, while values in
(0.5, 1] suggest some surrogate value.
A weight function is included in EAE(w), and thus PAE(w), to allow the pa-
rameters to reﬂect the idea that a biomarker with high surrogate value should have
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large |CEP risk(s1, s0)| for large |s1 − s0|. For example, weights w(s1, s0) = |s1 − s0|
or I(s1 = U, s0 = L) may be used, where L (U) is the lower (upper) bound of S.
With the latter weight, PAE(w) compares the clinical eﬀect among groups with the
maximum surrogate eﬀect and with no surrogate eﬀect: PAE(w) = |CEP R(1, 0)|/
[|EDE|+ |CEPR(1, 0)|].
If h(x, y) = x − y, Pr(S1(1) > Si(0)) = 0.5, and an additional monotonicity
assumption is made (that Yi(1) ≤ Yi(0) for all i, i.e., no one is harmed by treatment
1), then PAE(w = 1) equals the proportion associative (PA), deﬁned by
PA ≡
Pr(Si(1) > Si(0), Yi(1) = 0, Yi(0) = 1)
Pr(Yi(1) = 0, Yi(0) = 1)
.
This summary measure, proposed by Taylor, Wang, and Thiebaut (2005), is interpreted
as the proportion of the study population with a beneﬁcial causal clinical eﬀect that
also has a positive causal surrogate eﬀect. Note that the PA depends on the underlying
principal strata distribution F(1),(0)(s1, s0) = Pr(S(1) ≤ s1, S(0) ≤ s0); if Pr(Si(1) >
Si(0)) is small (large) then the PA will tend to be small (large), irrespective of the
surrogate value of the biomarker. By conditioning on (Si(1), Si(0)), the PAE(w) is
designed to be robust to F(1),(0)(·, ·); the PAE(w) reﬂects the relative magnitude of
clinical eﬀects for those with and without surrogate eﬀects.
Note that biomarkers satisfying Average Causal Necessity have EDE = 0 and
thus PAE(w) = 1, in which case EAE(w) contributes no information in the PAE(w).
Therefore other summary measures are needed to compare multiple biomarkers satisyf-
ing Average Causal Necessity, and more generally for better summarizing the mag-
nitude of associative eﬀects. The EAE(w) itself may be useful for this purpose,
as may contrasts of |EAE(w)| with |EDE| other than the PAE(w). For exam-
ple, with w(s1, s0) = I(s1 = U, s0 = L), the diﬀerence |EAE(w)| − |EDE| equals
AS ≡ |CEPR(1, 0)| − |EDE|, which we refer to as the associative span (AS). Table 1
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illustrates EAE(w = 1), EDE, PAE(w = 1), and AS for two hypothetical biomarkers
S. The ﬁrst has high (in fact perfect) surrogate value, with PAE(w = 1) = AS = 1,
and the second has no surrogate value, with PAE(w = 1) = 0.5 and AS = 0.
While the summary parameters may be useful, in general it is important to estimate
the CEP surface over the whole range of marker values or quantiles, to provide a full
picture of the associative and disssociative eﬀects.
4. Estimating the Causal Eﬀect Predictiveness Surface
4.1 Identiﬁability of the Causal Eﬀect Predictiveness Surface
Due to missing potential outcomes the CEP surface is not identiﬁed without further
assumptions. A1-A3 imply
risk(1)(s1, s0) = Pr{Y
obs
i = 1|Zi = 1, V
obs
i = 1, S
obs
i = s1, Si(0) = s0} and
risk(0)(s1, s0) = Pr{Y
obs
i = 1|Zi = 0, V
obs
i = 1, Si(1) = s1, S
obs
i = s0},
demonstrating that risk(1)(s1, s0) would be identiﬁed if the Si(0)’s of arm Z = 1
subjects were known, and similarly risk(0)(s1, s0) would be identiﬁed if the Si(1)’s of
arm Z = 0 subjects were known. Estimating the CEP surface will therefore require
a study design and plausible assumptions that provide a way to predict the missing
potential biomarker outcomes. While generally challenging, these requirements are
attainable in the important special case A4. Under A4 the joint values (Si(1), Si(0)) are
observed or known for all subjects in arm Z = 1, so that risk(1)(s1, c) = risk(s1|Z = 1),
i.e., risk(1)(s1, c) is identiﬁed by the observed data in arm Z = 1. However, risk(0)(s1, c)
is still not identiﬁed, and the remaining task to identify the CEP surface entails
determining values Si(1) for arm Z = 0 subjects.
An additional advantage under A4 is that the Average Causal Necessity criterion
is greatly simpliﬁed, to CEP risk(c, c) = 0. Thus the CEP surface only has to be
estimated at a single biomarker value to check this property. Furthermore, in case A4
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it is diﬃcult to evaluate a statistical surrogate, because it is not possible to study the
correlation of Sobsi with Y
obs
i in arm Z = 0 subjects, and it is conceptually diﬃcult to
evaluate whether S fully mediates clinical treatment eﬀects (Chan et al., 2002).
4.2 Baseline Predictor Study Design and Likelihood
Under A1-A4 and a standard clinical trial design with S binary, recently devel-
oped methods (for a diﬀerent application) provide estimators of CEP risk(0, 0) and
CEP risk(1, 0), as well as of PAE(w) and AS (Hudgens and Halloran, 2006; Shepherd et
al., 2006). These sensitivity analysis methods posit a class of non-identiﬁed models for
the post-randomization selection bias, and repeat the estimation under each model. Al-
ternatively, in the current work, for S continuous or categorical we leverage an innova-
tive trial design to develop a non-sensitivity analysis approach for estimating the CEP
surface. Throughout we assume A1-A4 and that the constant value c for Si(0) is the re-
alized lower bound L of the biomarker S(1), c = L = min{Si(1)} = min{S
obs
i |Zi = 1}.
The estimation approach is based on Follmann (2006), who proposed augmented
vaccine trial designs for discerning if an immunological correlate of HIV infection risk
causatively impacts infection risk. Follmann did not develop this work as a method for
evaluating a principal surrogate, and here we show how it can be built upon to provide
a technique for estimating the CEP surface. Follmann proposed two techniques for
predicting S(1) for arm Z = 0 subjects, of which we consider the ﬁrst, wherein a
baseline covariate vector W that is predictive of S(1) is measured in subjects in both
treatment arms. The correlation of W and S(1) observed in subjects assigned arm
Z = 1 is used to predict S(1) for subjects in arm Z = 0. A1-A3 imply S(1)|Z =
1, V obs = 1,W =d S(1)|Z = 0, V obs = 1,W , ensuring validity of this procedure. Several
potential baseline predictors are being collected in the ongoing HIV vaccine eﬃcacy
trials (Mehrotra, Li, and Gilbert, 2006).
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To develop an estimation procedure using the baseline predictor W , we assume W
does not predict clinical risk after accounting for S(1):
A5: Y (Z)|W,S(1) =d Y (Z)|S(1), Z = 0, 1.
We consider a case-cohort sampling design, in which a sub-sample of trial participants
is selected for measurement of Wi, which includes all cases and a “sub-cohort” of
controls. The biomarker Sobsi is measured for all arm Zi = 1 subjects for whom Wi is
measured. Case-cohort sampling is eﬃcient when Wi or Si is an expensive covariate
(Prentice, 1986). For HIV vaccine trials, Si(1) (and likely components of Wi) can be
measured after the trial using stored blood samples (Gilbert et al., 2005).
Let δi indicate whether Wi is measured. We observe iid data Oi ≡ (Zi, V
obs
i , Y
obs
i , δi,
δiWi, δiZiS
obs
i ), i = 1, . . . , n. Subjects i with V
obs
i = 1 contribute terms to the likeli-
hood. For subjects with Ziδi = 1, Pr(Y
obs
i = 1|Zi = 1, V
obs
i = 1, S
obs
i ) = risk(1)(S
obs
i , 0; β),
where risk(1)(S
obs
i , 0; β) is modeled as a function of unknown parameters β. The
likelihood contribution for subjects with (1 − Zi)δi = 1 is obtained by integrating
risk(0)(Si(1), 0; β) over the conditional cdf G
S|W of S(1)|W , Pr(Y obsi = 1|Zi = 0, V
obs
i =
1,Wi) =
∫
risk(0)(s1, 0; β)dG
S|W (s1|Wi); note that A5 is used here. Subjects with δi = 0
contribute Pr(Y obsi = 1|Zi, V
obs
i = 1) =
∫
risk(Zi)(s1, 0; β)dG
S(s1), where G
S is the cdf
of S(1). Thus the likelihood is L(β,GS|W , GS) ≡
∏n
i=1 f(Oi)
V obs
i , where f(O) equals{
risk(1)(S
obs, 0; β)Y
obs
(1− risk(1)(S
obs, 0; β))1−Y
obs
}Zδ
×
{(∫
risk(0)(s1, 0; β)dG
S|W (s1|W )
)Y obs (
1−
∫
risk(0)(s1, 0; β)dG
S|W (s1|W )
)1−Y obs}(1−Z)δ
×
{(∫
risk(Z)(s1, 0; β)dG
S(s1)
)Y obs (
1−
∫
risk(Z)(s1, 0; β)dG
S(s1)
)1−Y obs}(1−δ)
.
Since CEP risk(s1, 0; β) depends on β but not G
S|W and GS, these cdfs are nui-
sance parameters. Although proﬁle likelihood is thus a natural approach to pursue,
it is diﬃcult to implement because the likelihood integrates over GS|W and GS. An
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alternative approach would estimate (β,GS|W , GS) by full maximum likelihood; how-
ever this would require speciﬁcation of the joint distribution of (W,S(1)) and complex
numerical integration. We use estimated likelihood (Pepe and Fleming, 1991), wherein
consistent estimates of GS|W and GS are obtained based on treatment arm 1 data, and
then L(β, ĜS|W , ĜS) is maximized in β. The bootstrap can be used to get standard
errors for β̂. A re-sampling approach seems to be required because in general there is
no analytic expression for the asymptotic variance of β̂ that accounts for the variations
in ĜS|W and ĜS, and previously developed techniques for deriving the asymptotic vari-
ance of β̂ do not apply because they would assume that all subjects have a non-zero
probability that S(1) is observed (e.g., Pepe and Fleming 1991).
4.3 Models for risk(Z), G
S|W , and GS
An advantage of the estimated likelihood approach is that it can be used generally
for a variety of models for risk(Z)(·, ·), G
S|W , and GS. The dimensionality of W and S
determine whether parametric modeling assumptions are needed for stably estimating
GS|W and GS. For the case that δi = 1 for all i, Follmann considered a fully parametric
model, with (W,S(1)) assumed bivariate normal and Pr(Y (Z) = 1|S(1) = s1) assumed
to follow a probit model, for Z = 0, 1.
We allow case-cohort sampling and focus on the setting that S has J categories
and W has K categories. In this case nonparametric models can be used: with
θjk ≡ Pr(S(1) = j,W = k|V
obs = 1), gS(j) = Pr(S(1) = j|V obs = 1) =
∑K
k=1 θjk ≡ θj ,
gS|W (j|k) = θjk/
∑J
l=1 θlk, and risk(Z)(j, 0; β) = βZj, for Z = 0, 1; j = 1, . . . , J ; k =
1, . . . , K. Then for any h(·, ·) contrast function CEP risk(j, 0; β) = h(β1j , β0j), AS =
|h(β1J , β0J)| − |h(β11, β01)|, EAE(w) = (1 − θ1)
−1∑J
j=2 w(j, 1)h(β1j , β0j)Pr(S
obs =
j|Z = 1), and EDE = θ−11 h(β11, β01)Pr(S
obs = 1|Z = 1).
4.4 Nonparametric Maximum Estimated Likelihood Estimation (MELE)
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For estimating GS|W and GS, a consistent estimator of θjk based on treatment
Z = 1 data is given by
θ̂jk = θ̂
−1
j {(n1(j, k)/n1)AR + (n0(j, k)/n0)(1−AR)} ,
where θ̂j = (n1(j)/n1)AR + (n0(j)/n0)(1 − AR), AR =
∑n
i=1 ZiV
obs
i I[Y
obs
i = 1]/∑n
i=1 ZiV
obs
i , ny(j, k) =
∑n
i=1 ZiV
obs
i δiI[Y
obs
i = y, S
obs
i = j,Wi = k], ny(j) =
∑n
i=1 Zi
V obsi δiI[Y
obs
i = y, S
obs
i = j], and ny =
∑n
i=1 ZiV
obs
i δiI[Y
obs
i = y], for y = 0, 1.
To maximize L(β, ĜS|W , ĜS) it is convenient to partition β = (β1, β0)
′, where
risk(Z)(·, ·) depends on βZ ≡ (βZ1, . . . , βZJ)
′ only, Z = 0, 1. Then the estimated
likelihood factors as L(β, ĜS|W , ĜS) = L1(β1, Ĝ
S|W , ĜS) × L0(β0, Ĝ
S|W , ĜS), where
L1 =
∏n
i=1 f(Oi)
ZiV
obs
i and L0 =
∏n
i=1 f(Oi)
(1−Zi)V obsi . Based on L1 a closed form MELE
of β1j, j = 1, . . . , J can be derived as β̂1j = (n1(j)/n1) × (AR/θ̂j). An EM algorithm
can be used to ﬁnd the MELE of the β0j . The E step entails computing the expec-
tation of Iij ≡ I[S
obs
i = j] given the observed data. For δi = 0, E[Iij |Zi = 0, V
obs
i =
1, Y obsi = y, δi = 0] = {β
Y obs
i
0j (1 − β0j)
1−Y obs
i θ̂j}/{
∑J
l=1 β
Y obs
i
0l (1 − β0l)
1−Y obs
i θ̂l}, and for
δi = 1, E[Iij |Zi = 0, V
obs
i = 1, Y
obs
i = y, δi = 1,Wi = k] = {β
Y obs
i
0j (1 − β0j)
1−Y obs
i θ̂jk}/
{
∑J
l=1 β
Y obs
i
0l (1 − β0l)
1−Y obs
i θ̂lk}. The M step entails replacing Iij with µij ≡ E[Iij |Zi =
0, V obsi = 1, Y
obs
i = y, δi, δiWi] in the complete data likelihood, which when maximized
yields β̂0j = {
∑n
i=1(1− Zi)V
obs
i I[Y
obs
i = y]µij}/{
∑n
i=1(1− Zi)V
obs
i µij}.
4.5 Tests for Whether a Biomarker has Any Surrogate Value
Since PAE(w) = 0.5 supports that S has no surrogate value, Wald tests for any
surrogate value can be based on the MELE ̂PAE(w) minus 0.5 divided by its bootstrap
standard error. Similarly Wald tests of AS = 0 can be implemented based on ÂS.
We also consider a test statistic T =
∑J
j=2(j − 1){β̂0j − (β̂0j + β̂1j)(µ̂0/(µ̂0 + µ̂1))}
divided by its bootstrap standard error, where µ̂Z =
1
J
∑J
j=1 β̂Zj. This test evaluates
H0 : CEP
risk(j, 1) = CE for all j versus the monotone alternative that CEP risk(j, 1)
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increases in j, and is similar to the Breslow-Day test for trend (Breslow and Day, 1980).
5. Simulation Study
We are preparing to apply the methods to forthcoming datasets (Mehrotra, Li, and
Gilbert, 2006). In the interim, based on data from the ﬁrst preventive HIV vaccine
eﬃcacy trial (Gilbert et al., 2005), we conducted a simulation study to evaluate perfor-
mance of the nonparametric MELE method. The vaccine trial was double-blind with
2:1 randomization to vaccine:placebo. A biomarker of interest S was the percentage
of antibody blocking of the binding of the HIV GNE8 recombinant gp120 molecule to
recombinant soluble CD4 (the “CD4 blocking level”) measured from a serum sample
drawn at the month 6.5 visit after randomization, and Y was HIV infection during
the 3 year follow-up period. The lower quantiﬁcation limit of the CD4 blocking assay
was 0.084, and all 46 placebo recipients with S measured had Sobsi < 0.084; thus the
data ﬁt case A4. The range of Sobsi was [0.084, 0.92], which we rescaled to [0, 1], so
that A4 holds with c = L = 0. In vaccine recipients Sobsi was approximately normally
distributed, with average 0.576 and variance 0.0238.
We simulated vaccine trials with the following steps. Step 1: For all 3330 (1691)
subjects in the vaccine (placebo) arm, (Wi, Si(1)) was generated from a bivariate normal
distribution with means 0.576, variances 0.0238, and correlation ρ = 0.5, 0.7, or 0.9.
Then Wi and Si(1) were binned into quartiles. Step 2: For subjects i with quartile
j value of Si(1), Yi(Z) was generated from Bernoulli(βZj), with the βZj set to achieve
the infection rate Pr(Y (1) = 1) = 0.057 that was observed in the vaccine arm of the
trial and overall vaccine eﬃcacy of 50% (Pr(Y (0) = 1) = 2 × Pr(Y (1) = 1)), and
to reﬂect a biomarker with either (i) no or (ii) high surrogate value. In scenario (i)
CEP risk(j, 1; β) ≡ log(risk(1)(j, 1; β1)/risk(0)(j, 1; β0)) = −0.69 for j = 1, . . . , 4, and
in scenario (ii) CEP risk(j, 1; β) = −0.22,−0.51,−0.92,−1.61 for j = 1, . . . , 4. With
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vaccine eﬃcacy V E(j, 1) ≡ 1 − exp(CEP risk(j, 1; β)), scenario (i) speciﬁes constant
V E(j, 1) = 0.5 and scenario (ii) speciﬁes V E(j, 1) = 0.2, 0.4, 0.6, 0.8 for j = 1, . . . , 4.
Step 3: To achieve case-cohort sampling, (Wi, Si(1)) was retained for all infected
vaccine recipients and for the 406 uninfected vaccine recipients who had immunological
assays performed, and was set to missing for all other vaccine recipients. For the placebo
arm Si(1) was set to missing for everyone and Wi was retained for all infected placebo
recipients and for a random sample of 406 uninfected placebo recipients.
For each of 1000 simulated data sets the MELE β̂ was computed, which was then
used to compute the MELEs of CEP risk(j, 1), AS, and ̂PAE(w) for w(s1, s0) = 1, |s1−
s0|, and I(s1 = 4, s0 = 1). Wald tests (with bootstrap standard errors) based on
̂PAE(w)− 0.5 ÂS, and on T were used to test for any surrogate value.
Performance of the MELE β̂ was excellent (Table 2). The MELEs of CEP risk(j, 1)
also performed well, though with some bias. This bias results from the facts that
ĈEP
risk
(j, 1) involves the ratio β̂1j/β̂0j , and estimators deﬁned by the ratio of two es-
timators, each of which is unbiased for its estimand, may be biased in moderate samples
(Chick, Barth-Jones, and Koopman, 2001). In contrast the MELEs of CEP risk(j, 1)
with h(x, y) = x− y were unbiased (results not shown).
The MELEs of PAE(w) and AS were unbiased and the conﬁdence intervals about
them had nominal coverage. The tests for any surrogate value had approximately
nominal size and showed high power to detect surrogate value when ρ was 0.7 or
higher; the trend test had power 0.73, 0.91, and 0.99 for ρ = 0.5, 0.7, and 0.9. These
results demonstrate “proof-of-principle” that the methods can reliably estimate the
CEP surface when a reasonably good baseline predictor of the biomarker is used, and
can distinguish between biomarkers S with no or high surrogate value.
6. Discussion
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A main use of a surrogate endpoint is predicting treatment eﬀects on a clinical end-
point. Within the principal surrogate framework, we have introduced the causal eﬀect
predictiveness (CEP ) surface as an appropriate estimand for measuring the predictive
capacity of a candidate surrogate. The CEP surface is not identiﬁed from the data col-
lected in a standard trial design, however. On the other hand, the net eﬀect estimand
used in the alternative framework for evaluating surrogates (statistical surrogates) is
identiﬁed, but is not causal, which may make it less useful for measuring predictive
capacity. Therefore when applied to a single trial, each framework for deﬁning and
evaluating surrogates has a serious but diﬀerent limitation. As such, both approaches
may be useful for generating preliminary evidence about approximate surrogacy, which
will require further validation. In fact, based on a single eﬃcacy trial neither approach
is suitable for evaluating whether a biomarker can be reliably used for bridging infor-
mation about clinical eﬃcacy to a new setting (e.g., bridge to a new human population
or treatment formulation); for this additional experiments (such as mechanistic studies
and studies that deliberately manipulate the biomarker) and meta-analysis are needed.
Since the deﬁnition of the CEP surface involves counterfactuals, strong untestable
assumptions may be needed to identify it, which may preclude its reliable estimation.
While we think this critique will sometimes hold, a thesis of this work is that given
innovative data collection and a particular kind of biomarker S, the CEP surface can
be identiﬁed and estimated under plausible assumptions. The estimation method we
developed requires A1-A5, a reasonably good baseline predictor W , a model predicting
Sobs from W in treatment arm 1, and models for risk(Z)(s1, c) ≡ Pr(Y (Z) = 1|S(1) =
s1, S(0) = c), for Z = 0, 1. A1-A2 are standard in randomized trials, and A4 is easy
to check. A1 (SUTVA) is a potentially dubious assumption in the infectious disease
setting where dependent happenings are possible (Halloran and Struchiner, 1995), but
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should approximately hold in trials with a small study population relative to the total
population of at risk individuals. While untestable, A3 will not signiﬁcantly inﬂuence
the results if S is measured near baseline or if most randomized subjects are disease
free at its measurement time, but otherwise it will be important to conduct sensitivity
analyses to violations of A3. A5 is testable for treatment arm Z = 1 but not for
Z = 0. Thus it is important to evaluate plausibility of Y (0)|W,S(1) =d Y (0)|S(1)
from biological knowledge. Under A1-A5 any parametric modeling assumptions placed
on risk(1)(s1, c) and risk(0)(s1, c) can be tested. Finally, models for S
obs given W can
be directly checked using arm Z = 1 data.
A vector of baseline covariates X measured on all subjects could easily be incor-
porated into the developed estimation methods. This would allow modifying A5 to
the more defensible assumption A5′: Y (Z)|X,W, S(1) =d Y (Z)|X,S(1), Z = 0, 1. It
would also allow addressing the interaction question of how the CEP surface depends
on X, and could increase the precision for estimating the CEP surface. Furthermore,
to accommodate study drop-out that leads to missing Y ’s, including covariates could
help justify a missing at random assumption, facilitating making unbiased inferences.
To allow for drop-out A3 must be modiﬁed to A3′: Equal Individual Clinical Risk and
Drop-out Up to Time t0: Vi(1) = 1 if and only if Vi(0) = 1, where now Vi(Z) is the
potential indicator of whether the ith subject is at risk for disease at t0.
The estimands and estimation techniques developed here for a binary clinical end-
point Y also apply for a quantitative clinical endpoint Y , with all expressions Pr(Y (Z) =
1|·) replaced with E(Y (Z)|·). In either case the CEP surface describes how the av-
erage or population level causal eﬀect on Y depends on the causal eﬀect on S. It is
beyond the scope of this article to address the statistical generalizability of S, that
is, how reliably it can be used for predicting Y obs in a new setting. We note that the
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estimated CEP surface may be useful for this purpose, by providing a prediction of
the overall clinical eﬀect CE in the new setting based on measurements of S, which
could be compared to an estimate of CE computed ignoring S.
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Table 1
Examples illustrating a principal surrogate compared to a statistical surrogate, S
binary with Si(0) = 0 for all i, with h(x, y) = 1− x/y
Perfect Principal Surrogate but Not a Statistical Surrogatea
Sobsi /
Principal Fraction Pr(Yi(1) = 1| Pr(Yi(0) = 1| Pr(Y
obs
i = 1|S
obs
i , Zi)
Stratum (PS) (Si(1),Si(0)) in PS Si(1), Si(0)) Si(1), Si(0)) Zi = 1 Zi = 0
Vacc. not take (0,0) 1/3 0.3 0.3 0/0.3 0/0.2
Vacc. take (1,0) 2/3 0.0 0.15 1/0.0 0/0.2
No Value as a Principal Surrogate but a Statistical Surrogateb
Sobsi /
Principal Fraction Pr(Yi(1) = 1| Pr(Yi(0) = 1| Pr(Y
obs
i = 1|S
obs
i , Zi)
Stratum (PS) (Si(1),Si(0)) in PS Si(1), Si(0)) Si(1), Si(0)) Zi = 1 Zi = 0
Vacc. not take (0,0) 1/3 0.2 0.4 0/0.2 0/0.2
Vacc. take (1,0) 2/3 0.05 0.1 1/0.0 0/0.2
aCE = 1− [(1/3) × 0.3 + (2/3) × 0.0]/[(1/3) × 0.3 + (2/3) × 0.15] = 0.5;
Pr(Y obsi = 1|S
obs
i = 0, Zi = 1) = (1)× 0.3 = 0.3;
Pr(Y obsi = 1|S
obs
i = 0, Zi = 0) = (1/3) × 0.3 + (2/3) × 0.15 = 0.2;
CEP risk(0, 0) = 1− 0.3/0.3 = 0.0; CEP risk(1, 0) = 1− 0.0/0.15 = 1.0;
EAE(w = 1) = (2/3) × 1.0/(2/3) = 1.0, EDE = (1/3) × 0.0/(1/3) = 0.0;
PAE(w = 1) = 1.0/(0.0 + 1.0) = 1.0; AS = 1.0− 0.0 = 1.0
(the parameters EAE(w), EDE, and PAE(w) are deﬁned at (1)-(3)).
bCE = 1− [(1/3) × 0.2 + (2/3) × 0.05]/[(1/3) × 0.4 + (2/3) × 0.1] = 0.5;
Pr(Y obsi = 1|S
obs
i = 0, Zi = 1) = (1)× 0.2 = 0.2;
Pr(Y obsi = 1|S
obs
i = 0, Zi = 0) = (1/3) × 0.4 + (2/3) × 0.1 = 0.2;
CEP risk(0, 0) = 1− 0.2/0.4 = 0.5; CEP risk(1, 0) = 1− 0.05/0.1 = 0.5;
EAE(w = 1) = (2/3) × 0.5/(2/3) = 0.5; EDE = (1/3) × 0.5/(1/3) = 0.5;
PAE(w = 1) = 0.5/(0.5 + 0.5) = 0.5; AS = 0.5− 0.5 = 0.0
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Figure Legends
Figure 1. Example CEPR(v1, v0) = h(R(1)(v1, v0), R(0)(v1, v0)) surfaces, with h(x, y) =
x − y or 1 − x/y. The surface in (i) reﬂects a biomarker with no surrogate value
(PAE(w = 1) = 0.5, AS = 0), wherein the clinical treatment eﬀect is the same for all
treatment eﬀects on the biomarker. The surface in (ii) reﬂects a biomarker with high
surrogate value (PAE(w = 1) = 1, AS = 1), wherein the average causal eﬀect on the
clinical endpoint is zero for all v1 ≤ v0 and has a large increase in v1 − v0 for v1 > v0.
Because CEPR(v1, v0) = 0 for all v1 ≤ v0 and CEP
R(v1, v0) > 0 for all v1 > v0,
the biomarker evaluated in (ii) satisﬁes Average Causal Necessity and Average Causal
Suﬃciency, and hence is a principal surrogate.
Figure 2. For the situation A4 for which Si(0) = c for all i with c = L the lower
bound of S, biomarkers S that have no (horizontal solid line), modest (dashed line),
moderate (dotted line), and high (hatched line) surrogate value. With h(x, y) = x− y,
the area between each |CEPR(v1, F(1)(c))| curve and the zero-line equals the over-
all clinical treatment eﬀect |CE| = 0.4. Because CEPR(F(1)(c), F(1)(c)) = 0 and
CEPR(v1, F(1)(c)) > 0 for all v1 > F(1)(c), the latter two S’s satisfy Average Causal
Necessity and Average Causal Suﬃciency, and hence are principal surrogates.
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